Defining the molecular evolution of extrauterine high grade serous carcinoma.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
11 2019
Historique:
received: 01 05 2019
revised: 23 08 2019
accepted: 25 08 2019
pubmed: 9 9 2019
medline: 4 12 2019
entrez: 9 9 2019
Statut: ppublish

Résumé

High grade serous carcinoma (HGSC) is the most common and most aggressive, subtype of epithelial ovarian cancer. It presents as advanced stage disease with poor prognosis. Recent pathological evidence strongly suggests HGSC arises from the fallopian tube via the precursor lesion; serous tubal intraepithelial carcinoma (STIC). However, further definition of the molecular evolution of HGSC has major implications for both clinical management and research. This study aims to more clearly define the molecular pathogenesis of HGSC. Six cases of HGSC were identified at the Northern Ireland Gynaecological Cancer Centre (NIGCC) that each contained ovarian HGSC (HGSC), omental HGSC (OMT), STIC, normal fallopian tube epithelium (FTE) and normal ovarian surface epithelium (OSE). The relevant formalin-fixed paraffin embedded (FFPE) tissue samples were retrieved from the pathology archive via the Northern Ireland Biobank following attaining ethical approval (NIB11:005). Full microarray-based gene expression profiling was performed on the cohort. The resulting data was analysed bioinformatically and the results were validated in a HGSC-specific in-vitro model. The carcinogenesis of HGSC was investigated and showed the molecular profile of HGSC to be more closely related to normal FTE than OSE. STIC lesions also clustered closely with HGSC, indicating a common molecular origin. This study provides strong evidence suggesting that extrauterine HGSC arises from the fimbria of the distal fallopian tube. Furthermore, several potential pathways were identified which could be targeted by novel therapies for HGSC. These findings have significant translational relevance for both primary prevention and clinical management of the disease.

Identifiants

pubmed: 31493898
pii: S0090-8258(19)31481-7
doi: 10.1016/j.ygyno.2019.08.029
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

305-317

Subventions

Organisme : Medical Research Council
ID : MC_PC_17175
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

James P Beirne (JP)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Centre for Gynaecological Cancer, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland. Electronic address: j.beirne@qub.ac.uk.

Darragh G McArt (DG)

Department of Cancer Bioinformatics, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Aideen Roddy (A)

Department of Cancer Bioinformatics, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Clara McDermott (C)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Jennifer Ferris (J)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Niamh E Buckley (NE)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; School of Pharmacy, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Paula Coulter (P)

School of Pharmacy, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Nuala McCabe (N)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Sharon L Eddie (SL)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Philip D Dunne (PD)

Department of Translational Cancer Genomics, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Paul O'Reilly (P)

Department of Cancer Bioinformatics, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Alan Gilmore (A)

Department of Cancer Bioinformatics, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Laura Feeney (L)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland.

David Lyons Ewing (DL)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Ronny I Drapkin (RI)

Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Manuel Salto-Tellez (M)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Richard D Kennedy (RD)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland.

Ian J G Harley (IJG)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Centre for Gynaecological Cancer, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland.

W Glenn McCluggage (WG)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland; Northern Ireland Centre for Gynaecological Cancer, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland; Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom of Great Britain and Northern Ireland.

Paul B Mullan (PB)

Ovarian Cancer Research Programme, Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom of Great Britain and Northern Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH